Telix at ANZSNM Annual Scientific Meeting 2022
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15…
Read moreNews & Views
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New…
Read more
Telix Further Strengthens European Distribution Network for Illuccix
Telix announces agreements with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic…
Read more
Activities Report and Appendix 4C for March 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March…
Read more
First Patients Dosed with Illuccix® – Telix’s Approved Prostate Cancer Imaging Agent
Telix announces the first commercial doses of its prostate cancer imaging agent,…
Read more
Notice of Annual General Meeting 2022
Telix provides notice of The Annual General Meeting of Shareholders on Wednesday 18 May…
Read more
ProstACT Update: TARGET Study Ethics Approval
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee…
Read more
Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human…
Read more
PSMA-PET Imaging to be Funded through Medicare in Australia from July
Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July…
Read more
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
Telix announces that it is part of a $71.2 million Australian Precision Medicine Enterprise Project, which has been awarded $23 million in Federal Government…
Read more